Table 6.
Group A, eGFR ≥30, UP-UCR <0.5 | Group B, eGFR ≥30, UP-UCR ≥0.5 | Group C, eGFR <30 | Pa | |
---|---|---|---|---|
No. patients | 254 | 416 | 32 | |
M1 (%) | 3 | 16b | 31b | <0.01 |
En1 (%) | 36 | 45b | 44 | 0.05 |
S1 (%) | 67 | 86b | 84 | <0.01 |
Ex1 (%) | 47 | 71b | 78b | <0.01 |
Tubular atrophy/interstitial fibrosis | <0.01 | |||
<25 (%) | 91 | 63a | 3b,c | |
25 to 50 (%) | 7 | 24 | 9 | |
50<(%) | 2 | 12 | 88 |
The number is the percentage of patients with each pathologic parameter. Abbreviations: M1, mesangial hypercellularity in >50% of glomeruli; En1, presence of endocapillary hypercellularity; S1, presence of segmental glomerulosclerosis; Ex1, presence of extracapillary proliferation.
P value by analysis of variance or the chi-squared test.
Significantly different from group A by multiple comparison of the chi-squared test.
Significantly different from group B by multiple comparison of the chi-squared test.